Abstract: A method for removal of contaminants in a sample of AAV comprising the steps of loading the sample to an affinity chromatography column, washing the column after the sample is loaded with a first buffer comprising a compound having at least three positive charges or at least three negative charges employing a second buffer having a salt concentration corresponding to a concentration of at least 0.25 M NaCl for displacing the compound wherein neither the compound nor the salt is present in a concentration sufficient to elute the AAV.

Abstract: Provided herein are methods for the purification of recombinant adeno-associated virus (rAAV) vectors that can be used for gene transfer and specifically for gene therapy or vaccination. Recombinant AAV vectors of the invention are substantially free of in-process impurities, including production components such as cellular nucleic acids, cellular proteins, helper virus, and media components.

Abstract: A chromatographic method for separation of lipid-membrane-enclosed compound assemblages (LMCAs) from chromatin heteroaggregates including degraded remnants from LMCAs in a sample, contacting the sample with a chromatographic material with a surface having cationic metal affinity ligands said chromatographic material being charged with ferric iron, manganese, calcium, or magnesium ions, and being equilibrated with an equilibration buffer, applying a gradient of a first elution buffer comprising a non-metal-chelating salt, thereby eluting LMCAs.

Abstract: A method is disclosed for manufacturing a purified pDNA preparation from a sample comprising pDNA and a contaminant, the method comprising the steps of: Contacting the sample with a hydrophobic interaction chromatography (HIC) material in a solution comprising a kosmotropic salt in a concentration which forces the pDNA and contaminant to adsorb on the HIC material, Diluting the concentration of the kosmotropic salt in presence of a neutral salt subsequent to adsorbing of the pDNA on the HIC material, thereby Desorbing the pDNA from the HIC material, whereas the contaminant stays adsorbed by the continued presence of the neutral salt, and Obtaining the pDNA preparation. Furthermore, a method is disclosed for preparing a sample to be subjected to the method of the invention or other purification methods, in particular anion exchange chromatography by exposing the sample to a neutral salt in the presence of a HIC material.

Abstract: A method for removal of host cell DNA from a sample containing a species of desired protein, virus, or extracellular vesicle comprising the steps of: Loading a substrate bearing an anionic metal affinity ligand with a metal ion, Equilibrating the substrate with a buffer having a pH in the range of pH 6 to pH 10, and a salt concentration in a concentration range up to 1 M which salt is not forming a chemical complex with the anionic metal affinity ligand, Contacting the sample with the metal-loaded anionic metal affinity substrate, Separating the substrate from the sample, wherein the sample has reduced content of contaminating DNA.

Abstract: A method for separating full Adeno-associated virus (AAV) capsids from empty AAV capsids in a buffered mixture comprising full AAV capsids, empty AAV capsids, comprising the steps of contacting the buffered mixture with a first substrate bearing a metal affinity ligand attached to the first substrate, said metal affinity ligand having the ability to complex metal ions via three or more nitrogen atoms, separating empty AAV capsids from full AAV capsids by eluting with a pH gradient, a salt gradient, a metal ion gradient or a combination thereof in the presence of multivalent cations bound to the metal affinity ligand to obtain a purified full AAV capsid fraction.

Abstract: A method for reducing a contaminating DNA content of a preparation containing AAV capsids and contaminating DNA, comprising the steps of a) Performing an extraction of DNA with a solid phase bearing positive charges at its surface said solid phase is contacted with the preparation at a pH of 7.0±1.0, and a salt concentration of 10 mM to 200 mM yielding a first fraction, (b) Diafiltering the first fraction by a first tangential flow filtration to obtain a second fraction, (c) Treating the second fraction with DNase, (d) Diafiltering the DNase treated second fraction obtained by step c) by a second tangential flow, (e) filtration to a buffer with pH of 7.0±1.0, and a salt concentration of 10 mM to 20 mM to yield a third fraction, and optionally (f) Concentrating the third fraction by tangential flow filtration before supplemental chromatography.

Abstract: A method for the separation or depletion of empty AAV capsids from full AAV capsids in an aqueous mixture comprising empty and full AAV capsids, wherein the mixture is contacted with a primary amino groups bearing solid phase surface in a first alkaline milieu whereby (i) full AAV capsids bind to the solid phase surface whereas empty AAV capsids at least partially do not bind to the solid phase surface, or (ii) both full and empty AAV capsids bind to the solid phase surface, and subsequently the empty AAV capsids are at least partially eluted by means of a second alkaline milieu of a pH value higher than the pH value of the first alkaline milieu, with the proviso that the second alkaline milieu does not elute full AAV capsids from the solid phase surface.

Abstract: A method of single-stranded RNA purification comprising the steps applying a sample containing single-stranded RNA to a solid phase bearing dominantly or exclusively primary amino groups on its surface, at a pH value sufficient to bind at least predominantly the single-stranded RNA, eluting the single-stranded RNA from the surface of the solid phase by exposing the surface of the solid phase to increasing pH.

Abstract: A method of single-stranded RNA purification comprising the steps: applying a sample containing single-stranded RNA to a solid phase dominantly or exclusively bearing both primary and secondary amino groups on its surface under conditions sufficient to bind at least predominantly the single-stranded RNA, eluting the single-stranded RNA adsorbed on the surface of the solid phase from the solid surface by means of an elution buffer having a higher concentration of comprising soluble pyrophosphate anions than needed for desorbing double-stranded RNA.

Abstract: A method of single strand RNA purification employing an anion exchanger comprising the steps applying a sample containing single-stranded RNA to an anion exchanger, washing the anion exchanger at a first temperature in the range of 18° C. to 25° C. with a first salt solution having a first ionic strength in the range 0.5 M to 12.0 M, eluting the single stranded RNA by a second salt solution having a second ionic strength at a second temperature in the range of 35° C. to 80° C., with the proviso that the first ionic strength is at least 0.5 M higher than the second ionic strength.

Abstract: Provided herein are methods for the purification of recombinant adeno-associated virus (rAAV) vectors that can be used for gene transfer and specifically for gene therapy or vaccination. Recombinant AAV vectors of the invention are substantially free of in-process impurities, including production components such as cellular nucleic acids, cellular proteins, helper virus, and media components.

Abstract: Methods are disclosed for use of apatite chromatography, particularly without reliance upon phosphate gradients, for purification or separation of at least one intact non-aggregated antibody, or at least one immunoreactive antibody fragment, from an impure preparation. Integration of such methods into multi-step procedures with other fractionation methods are additionally disclosed.

Abstract: Provided herein are methods for the purification of recombinant adeno-associated virus (rAAV) vectors that can be used for gene transfer and specifically for gene therapy or vaccination. Recombinant AAV vectors of the invention are substantially free of in-process impurities, including production components such as cellular nucleic acids, cellular proteins, helper virus, and media components.

Abstract: Provided herein are methods for the purification of recombinant adeno-associated virus (rAAV) vectors that can be used for gene transfer and specifically for gene therapy or vaccination. Recombinant AAV vectors of the invention are substantially free of in-process impurities, including production components such as cellular nucleic acids, cellular proteins, helper virus, and media components.

Abstract: Provided herein are methods for the purification of recombinant adeno-associated virus (rAAV) vectors that can be used for gene transfer and specifically for gene therapy or vaccination. Recombinant AAV vectors of the invention are substantially free of in-process impurities, including production components such as cellular nucleic acids, cellular proteins, helper virus, and media components.

Abstract: Methods are disclosed for use of apatite chromatography, particularly without reliance upon phosphate gradients, for purification or separation of at least one intact non-aggregated antibody, or at least one immunoreactive antibody fragment, from an impure preparation. Integration of such methods into multi-step procedures with other fractionation methods are additionally disclosed.

Abstract: Methods are disclosed for use of apatite chromatography, particularly without reliance upon phosphate gradients, for purification or separation of at least one intact non-aggregated antibody, or at least one immunoreactive antibody fragment, from an impure preparation. Integration of such methods into multi-step procedures with other fractionation methods are additionally disclosed.

Abstract: Provided are methods and compositions for reducing or eliminating pH excursions in cation and anion exchange chromatography.

Abstract: Methods are disclosed for use of apatite chromatography, particularly without reliance upon phosphate gradients, for purification or separation of at least one intact non-aggregated antibody, or at least one immunoreactive antibody fragment, from an impure preparation. Integration of such methods into multi-step procedures with other fractionation methods are additionally disclosed.